Retatrutide Self-Mix Vial – 32mg
Product Overview
Retatrutide is a research compound investigated for its activity across three metabolic hormone pathways: GLP-1, GIP and glucagon receptors.
Unlike selective GLP-1 receptor agonists, retatrutide interacts with all three receptor systems. Research has focused on the combined effects of these pathways on appetite regulation, energy expenditure, glucose metabolism, lipid metabolism and body composition.
Retatrutide is an investigational compound. It is not registered as a medicine in South Africa and has not been evaluated by SAHPRA.
Product Specifications
- Active ingredient: Retatrutide
- Total amount: 32mg
- Format: Lyophilised powder for reconstitution
- Supplier: Noventra Pharma
- Administration: Subcutaneous
- Regulatory status: Research use only. Not a registered medicine in South Africa and not evaluated by SAHPRA.
Receptor Activity
GLP-1 Receptor
GLP-1 signalling is associated with appetite regulation, satiety, gastric motility and glucose metabolism.
GIP Receptor
GIP signalling is involved in nutrient metabolism, insulin-related pathways and energy regulation.
Glucagon Receptor
Glucagon receptor activity is associated with energy expenditure, lipid metabolism and mobilisation of stored energy.
Mechanism of Action
Research into retatrutide examines the combined effects of:
- Reduced appetite signalling
- Increased satiety
- Altered energy expenditure
- Glucose regulation
- Lipid utilisation
- Hepatic metabolic pathways
- Insulin signalling
- Changes in energy balance
Research Applications
Retatrutide research includes:
- Appetite and satiety signalling
- Energy expenditure
- Glucose metabolism
- Insulin-related pathways
- Lipid metabolism
- Fat oxidation
- Body-composition research
- Metabolic flexibility
- GLP-1, GIP and glucagon signalling
- Weight-management research
Dosage & Administration
The following figures are the supplied product dosing reference.
Dose Escalation
| Research Period | Weekly Dose |
|---|---|
| Weeks 1–4 | 2mg once weekly |
| Weeks 5–8 | 4mg once weekly |
| Weeks 9–12 | 8mg once weekly |
| From Week 13 | 12mg once weekly |
The supplied protocol states that the dose may be adjusted according to tolerance.
Frequency
Once weekly, preferably on the same day each week.
Timing
The supplied information states that retatrutide can be administered at any time of day, regardless of meals.
Changing the Dosing Day
The supplied protocol indicates that the weekly dosing day can be changed provided that at least 3 days have passed since the previous dose.
Administration
Retatrutide is supplied for subcutaneous administration.
The supplied product information identifies the following general administration areas:
- Upper arms
- Abdomen/stomach
- Upper legs/thighs
Do not administer intravenously or intramuscularly.
Reconstitution
This presentation is supplied as a lyophilised powder, with bacteriostatic water included in the box, and requires reconstitution before use. Our reconstitution guide walks through it step by step. Our reconstitution calculator will work out the concentration and dose volume for the vial size and dose you are using.
- Allow the vial to reach room temperature.
- Wipe the stopper with an alcohol swab.
- Introduce the bacteriostatic water slowly against the inside wall of the vial.
- Swirl gently until dissolved. Do not shake.
- Inspect the solution. Do not use if cloudy, discoloured or containing visible particles.
- Refrigerate once reconstituted and use within the period specified by the manufacturer.
Missed Dose
According to the supplied protocol:
- If the missed dose is 5 days or less overdue, administer it when remembered and continue with the normal schedule.
- If it has been more than 5 days, skip the missed dose and resume the normal weekly schedule.
- Do not administer an additional dose to compensate for a missed dose.
Potential Effects & Considerations
The supplied information identifies gastrointestinal and metabolic effects as areas to monitor, including:
- Nausea
- Vomiting
- Diarrhoea
- Reduced appetite
- Dehydration
- Dizziness
- Changes in blood glucose
- Gastrointestinal discomfort
Severe or persistent abdominal pain warrants prompt medical assessment because pancreatic inflammation can present with significant abdominal symptoms.
Individuals researching metabolic compounds should also consider relevant glucose, metabolic and clinical parameters.
Pregnancy & Breastfeeding
The supplied product information advises against use during pregnancy and breastfeeding and recommends discussing reproductive plans with an appropriate healthcare professional.
Storage & Handling
- Store refrigerated where required, or according to the manufacturer’s specified controlled-temperature conditions.
- Never freeze.
- If stored outside refrigeration, keep in a cool, dry environment within the specified temperature range.
- Keep the vial sealed and protected from light and excessive heat.
- Keep out of reach of children.
- Do not use beyond the stated expiry date.
- Inspect the solution before use and do not use if it is cloudy, discoloured or contains visible particles.
Self-Mix Format
Retatrutide Self-Mix Vial – 32mg is supplied as a lyophilised powder for reconstitution, which allows the researcher to select the working concentration rather than being fixed to a pre-set one.
Lyophilised material is also more stable in storage than a solution, which suits protocols run over a longer period.
Important Notice
Retatrutide Self-Mix Vial – 32mg contains retatrutide, a research compound investigated for activity across the GLP-1, GIP and glucagon receptor pathways.
The mechanisms, applications and dosing information provided above are based on the supplied product information and research references.
For research use only. Not intended for human consumption.
